Werewolf Therapeutics (NASDAQ: HOWL)

Grey Wolf Therapeutics

Grey Wolf Therapeutics develops antigen modulation treatments targeting cancer and autoimmune disorders to help the immune system recognise and destroy diseased cells.

Targovax AS (Oncos)

This biotechnology company develops circular RNA therapeutics and oncolytic virus-based immunotherapies for patients with solid tumours and other difficult-to-treat diseases.

ALXO

This biopharmaceutical company develops immune system therapies to treat cancer patients with solid tumors and hematologic malignancies.

Mustang Bio

This biopharmaceutical company develops gene and cell therapies for patients with hematologic cancers, solid tumours and rare genetic diseases.

Ultragenyx

This biopharmaceutical company develops and commercialises therapies for patients with serious rare and ultra-rare genetic diseases.

Xilio Therapeutics

This biotechnology company develops tumour-activated immuno-oncology therapies designed to treat patients with solid cancers while reducing systemic side effects.

Bicara Therapeutics

This biotechnology company develops dual-action biologics to treat patients with solid tumours by targeting the tumour microenvironment.

Silverback Therapeutics

This biopharmaceutical company develops immune-modulating therapeutics for patients with cancer and chronic viral infections.